1) Comparative trials and reports by healthcare professionals show that severe and sometimes incapacitating muscle, joint and bone pain can occur days, months or years after beginning long-term oral bisphosphonate therapy. Patients treated for osteoporosis are particularly at risk; 2) This type of pain affects between 2% and 5% of patients, especially those taking an oral bisphosphonate once a week; 3) The role of a bisphosphonate should be considered when a patient presents with musculoskeletal pain. Discontinuation of bisphosphonate therapy can be tried and may represent a better option than escalation of analgesic therapy.
展开▼
